Aims and objectives of workstreams

Read more
STEP Database

Safety and Toxicity of Excipients for Paediatrics

Read more

Become a member and support us.

Read more
News & Events

7th EUPFI Conference, September 2015

Read More

About EuPFI

European Paediatric Formulation Initiative (EuPFI) is a consortium working in a pre-competitive way on paediatric drug formulations. Members are from academia, hospital pharmacies, pharmaceutical industry (Innovators, Generics,Contract Research Organizations (CRO), Specials and Excipient Manufacturers) with European Medicine Agency (EMA) as an observer. It aims to expedite the development of better and safer medicines for children by identifying and scoping issues and challenges in paediatric formulation development. It brings together the voluntary, academic, pharmaceutical industry, hospitals and regulatory agency in order to tackle the development of age appropriate formulation for paediatrics. It provides funding, expertise and resources to support the solutions to the problems and new technologies emerging from academic research.

To promote and facilitate preparation of better & safe medicines for children through:

Sharing expertise and interactive discussion between industry, academia, clinical and regulatory professionals,
Information dissemination,
Raising awareness (publications, conferences etc),
linking and networking.

Identify the issues and challenges associated with development of paediatric formulation and consider ways towards better medications and clinically relevant dosage forms for children.
Promote early pharmaceutical consideration for development of paediatric medicines.
Identify potential information, knowledge, know-how gaps in the paediatric formulation development.
Improve the availability of information of paediatric formulations.

Quick Facts
Non profit organisation.
Established in London in 2007.
Members from industry, academia, hospital and regulatory agencies dedicated to fulfilling its mission.
Membership open to anyone interested in paediatric
formulation development.
5 Workstreams.
Annual Conferences.

Meet The Team

Our Structure and Operation

Networks & Collaborations

Global Research in Paediatrics – Network of Excellence (GRiP)


Global Research in Paediatrics (GRIP) is a European Commission funded program which aims to stimulate and facilitate the development and safe use of medicine in children.

United States Paediatric Formulation initiative (USPFI)


EuPFI and USPFI are working together on the common project to build a database gathering safety data on excipients used in paediatric formulations.

The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ)

iQ logo

The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) is a technically-focused organization of pharmaceutical and biotechnology companies with a mission of advancing science-based and scientifically-driven standards and regulations for pharmaceutical and biotechnology products worldwide. In January 2014 IQ joined the European Pediatric Formulation Initiative (EuPFI) to further efforts to promote global alignment on pediatric product development. EuPFI is a consortium that has been instrumental in driving science and science-based standardization for pediatric formulation development. Membership in EuPFI allows IQ and EuPFI to join forces in addressing a topic with public health significance.

European Study of Neonatal Excipient Exposure (ESNEE)

ESNEE logo

Excipients are used to facilitate the manufacturing of dosage forms and maintain the stability of medicines in the face of chemical and microbial challenges. The lack of neonatal safety information exposes these patients to the risk of specific adverse reactions unexpected from adult experience.

The ESNEE project, "Strategy for the extensive review of the literature on excipient toxicities" aimed to develop and validate a systematic and standardised search strategy for collecting relevant information about excipients.

Technology Strategy Board (TSB)

TSB logo

EuPFI in collaboration with its network of partners secured a £660,000 grant from the Technology Strategy Board, the UK’s innovation agency, towards a £1 million project aimed at accelerating paediatric formulation development through smart design and predictive science.

The consortium aimed to address the need for improved speed, cost and quality of paediatric formulation by drawing on the combined expertise of its members. The goal was to deliver a novel, commercially available, regulatory-approved platform to identify the most appropriate delivery strategy for paediatric medicines.

European Medicine Agency (EMA)

EMEA logo

The EMA acts as a continuous observer of EuPFI's research activities.

Enter Google username or id to start! Example: 116819034451508671546
File name
Link to
  Open new windows
  Rel nofollow